Kosmos Energy Ltd. Common Shares (DE) vs Natera Inc. Common Stock — how do they compare? Kosmos Energy Ltd. Common Shares (DE) trades at $2.71 (market cap $1.66B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 34.4× Kosmos Energy Ltd. Common Shares (DE)'s market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Kosmos Energy Ltd. Common Shares (DE) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kosmos Energy Ltd. Common Shares (DE) for 0 Days and Natera Inc. Common Stock for 0 Days on average.
| KOS | NTRA | |
|---|---|---|
Market Cap | $1.66B | $57.03B |
Volume | 7,535,344 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $3.27 | $425.64 |
52-Week Low | $0.87 | $179.42 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.30B | $56.18B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kosmos Energy Ltd. is a deepwater oil and gas exploration and production company with operations offshore Ghana, Equatorial Guinea, Mauritania, and Senegal in West Africa.
Read more on KOS →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →